Saturday 17 October 2026
Export PCRX’s income statement to Excel — free account
Pacira BioSciences, Inc.
PCRX Healthcare Drug Manufacturers Specialty & Generic
Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.24%, EPS grew 209.1%, free cash flow grew 502.5% and total debt fell 37.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
36.35
0.02
+0.06%
Follow PCRX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
172.53 | 0.00 | 35.56 | 109.50 | 63.34 | 17.70 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
8 | 5 | 8 | 6 | 4 | 4 | 5 | 6 | 5 | 4 |
P/S ratio |
1.59 | 1.24 | 2.19 | 2.65 | 4.92 | 5.94 | 4.47 | 5.22 | 6.43 | 4.68 |
Altman Z-Score |
2.02 | 1.12 | 2.16 | 1.80 | 1.65 | 2.89 | 2.68 | 3.37 | 3.22 | 3.99 |
P/FCF ratio |
8.44 | 4.87 | 10.60 | 15.36 | 33.35 | 65.09 | 31.15 | 51.23 | 0.00 | 147.98 |
Altman Z″-Score (non-manufacturers) |
3.08 | 2.14 | 3.17 | 2.22 | 1.62 | 2.64 | 1.68 | 3.21 | 2.05 | 1.22 |
Beneish M-Score |
(2.93) | (3.48) | (2.71) | (2.67) | (1.99) | (2.05) | (2.08) | (2.77) | (2.80) | (3.08) |
P/Operating CF |
26.40 | 26.30 | 31.08 | 42.08 | 114.72 | 54.72 | 72.60 | 82.94 | 108.85 | 74.58 |
P/B ratio |
1.66 | 1.12 | 1.70 | 2.28 | 3.65 | 4.12 | 5.30 | 5.48 | 6.59 | 5.91 |
Price to Tangible BV |
3.78 | 2.47 | 6.61 | 24.84 | 0.00 | 6.03 | 12.45 | 6.79 | 8.22 | 7.51 |
EV/Sales |
2.05 | 1.39 | 2.55 | 3.25 | 5.00 | 5.82 | 4.51 | 4.94 | 6.31 | 4.45 |
EV/EBITDA |
13.76 | 799.97 | 10.61 | 13.67 | 18.74 | 28.87 | 41.74 | 38.35 | 3,188.44 | 0.00 |
EV/Operating CF |
9.80 | 5.13 | 11.14 | 14.94 | 21.52 | 32.48 | 26.94 | 34.11 | 101.65 | 36.77 |
EV/FCF |
10.90 | 5.44 | 12.35 | 18.84 | 33.88 | 63.77 | 31.47 | 48.53 | (1,220.69) | 140.68 |
Quick Ratio |
3.01 | 1.93 | 3.94 | 2.62 | 1.44 | 2.27 | 3.15 | 6.95 | 6.10 | 4.52 |
Current Ratio |
4.54 | 2.40 | 5.24 | 3.37 | 1.66 | 2.57 | 3.79 | 7.88 | 6.96 | 5.42 |
Net Debt/EBITDA |
1.24 | 82.89 | 1.50 | 2.53 | 0.29 | (0.60) | 0.42 | (2.14) | (62.04) | 4.39 |
Debt/Assets |
29.42% | 37.68% | 33.18% | 41.01% | 33.67% | 36.88% | 37.43% | 42.15% | 43.95% | 27.78% |
Debt/Equity |
0.54 | 0.75 | 0.60 | 0.89 | 0.96 | 0.76 | 0.88 | 0.90 | 0.99 | 0.50 |
Asset Turnover |
0.52 | 0.45 | 0.41 | 0.36 | 0.32 | 0.41 | 0.55 | 0.51 | 0.56 | 0.71 |
Operating CF/Net income |
21.61 | (1.90) | 3.69 | 9.13 | 2.99 | 0.53 | (6.40) | (103.76) | (0.42) | (0.88) |
Capex/Depreciation |
(0.17) | (0.14) | (0.20) | (0.30) | (0.84) | (0.94) | (0.29) | (0.53) | (0.76) | (1.41) |
Interest Coverage |
1.10 | (4.43) | 4.32 | 1.50 | 2.83 | 1.81 | 0.44 | 0.73 | (1.38) | (4.54) |
| 0.96% | (12.08%) | 5.10% | 2.11% | 6.22% | 29.86% | (3.26%) | (0.16%) | (17.10%) | (17.35%) | |
| 0.50% | (6.37%) | 2.58% | 0.85% | 2.51% | 13.82% | (1.45%) | (0.07%) | (8.36%) | (9.74%) | |
ROIC |
1.45% | (5.22%) | 4.92% | 3.19% | 7.27% | 5.10% | 1.75% | 4.36% | (6.38%) | (12.90%) |
Return on Tangible Assets |
1.24% | (16.53%) | 7.15% | 2.98% | 7.87% | 27.20% | (2.72%) | (0.09%) | (9.64%) | (12.68%) |
Average Days of Receivables |
62.34 | 59.00 | 57.08 | 53.86 | 64.92 | 45.06 | 41.21 | 41.12 | 40.31 | 39.54 |
Research and Development Expense of Revenue |
16.15% | 11.64% | 11.30% | 12.72% | 10.26% | 13.83% | 17.13% | 16.51% | 19.99% | 16.53% |
Selling, General and Administrative Expense of Revenue |
50.76% | 41.96% | 39.92% | 38.17% | 36.81% | 45.04% | 47.69% | 52.56% | 56.34% | 55.22% |
Intangible Assets out of Total Assets |
0.31 | 0.27 | 0.41 | 0.42 | 0.37 | 0.15 | 0.25 | 0.09 | 0.09 | 0.12 |
Share Based Compensation of Revenue |
7.92% | 7.30% | 7.10% | 7.21% | 7.80% | 9.29% | 7.99% | 9.41% | 11.03% | 11.31% |
Graham Net Nets |
(0.02) | (0.03) | (0.13) | (0.23) | (0.18) | 0.00 | (0.04) | 0.06 | 0.02 | 0.05 |
Graham Number |
7.25 | 0.00 | 19.52 | 11.66 | 18.78 | 33.23 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
0.58% | (11.46%) | 2.81% | 0.91% | 1.58% | 5.65% | (0.60%) | (0.04%) | (2.35%) | (2.91%) |
Free Cash Flow Yield |
11.85% | 20.52% | 9.43% | 6.51% | 3.00% | 1.54% | 3.21% | 1.95% | (0.08%) | 0.68% |
Revenue per Share |
16.30 | 15.16 | 14.60 | 14.65 | 12.23 | 10.07 | 10.14 | 8.24 | 7.20 | 7.42 |
Operating CF per Share |
3.41 | 4.10 | 3.35 | 3.19 | 2.84 | 1.81 | 1.70 | 1.19 | 0.45 | 0.90 |
Capex per Share |
(0.34) | (0.23) | (0.33) | (0.66) | (1.04) | (0.89) | (0.24) | (0.35) | (0.48) | (0.66) |
Free Cash Flow per Share |
3.07 | 3.87 | 3.02 | 2.53 | 1.80 | 0.92 | 1.45 | 0.84 | (0.04) | 0.23 |
Cash per Share |
5.35 | 10.48 | 6.03 | 6.34 | 14.83 | 12.23 | 7.03 | 9.37 | 7.82 | 4.64 |
Shareholders Equity per Share |
15.55 | 16.83 | 18.83 | 17.03 | 16.50 | 14.52 | 8.55 | 7.85 | 7.02 | 5.88 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
15.55 | 16.83 | 18.83 | 17.03 | 16.50 | 14.52 | 8.55 | 7.85 | 7.02 | 5.88 |
Free Cash Flow |
136.66 | 178.75 | 139.49 | 115.20 | 79.85 | 39.23 | 60.36 | 34.36 | (1.48) | 8.74 |
Working Capital |
427.38 | 435.21 | 412.61 | 350.56 | 344.93 | 398.30 | 300.88 | 417.31 | 334.89 | 198.25 |
Capital Expenditures |
(15.33) | (10.64) | (15.16) | (30.08) | (45.87) | (37.80) | (10.16) | (14.51) | (19.27) | (24.71) |
Net Current Asset Value |
(23.83) | (30.04) | (194.26) | (407.86) | (478.90) | (3.20) | (67.56) | 109.84 | 42.22 | 70.60 |
EV/EBIT |
77.62 | 0.00 | 19.65 | 36.15 | 30.09 | 53.98 | 181.26 | 104.75 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.05 | 0.08 | 0.09 | 0.02 | 0.04 | 0.07 | 0.09 |
Price to Operating Income |
60.10 | 0.00 | 16.87 | 29.47 | 29.62 | 55.09 | 179.44 | 110.59 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.63 | 0.45 | 0.43 | 0.54 | 0.29 | 0.30 | 0.33 | 0.25 | 0.24 | 0.17 |
Cash ROIC |
10.48% | 9.67% | 8.35% | 6.57% | 3.83% | 2.43% | 6.30% | 3.45% | (0.17%) | 1.75% |
Accounts Receivable Turnover |
6.12 | 6.41 | 6.62 | 6.85 | 7.25 | 8.54 | 9.85 | 9.68 | 9.31 | 9.91 |
Accounts Payable Turnover |
8.74 | 9.79 | 11.95 | 15.47 | 13.37 | 10.10 | 7.86 | 5.98 | 7.93 | 13.55 |
Inventory Turnover |
1.08 | 1.48 | 1.84 | 2.05 | 1.72 | 1.91 | 2.00 | 1.93 | 2.42 | 2.37 |
Average Days of Payables |
36.93 | 40.98 | 31.03 | 27.87 | 27.44 | 32.45 | 43.78 | 60.39 | 60.86 | 24.90 |
Days of Inventory on Hand |
372.59 | 268.31 | 206.25 | 175.94 | 256.47 | 201.12 | 199.40 | 204.13 | 171.93 | 103.69 |
Average Receivables |
118.69 | 109.43 | 101.98 | 97.36 | 74.68 | 50.29 | 42.77 | 34.83 | 30.80 | 27.90 |
Average Payables |
17.14 | 17.42 | 15.46 | 12.88 | 10.49 | 11.62 | 13.58 | 14.51 | 11.08 | 8.13 |
Average Inventory |
139.07 | 114.82 | 100.21 | 97.31 | 81.60 | 61.47 | 53.43 | 44.99 | 36.34 | 46.46 |
Average Assets |
1,409.22 | 1,563.95 | 1,627.79 | 1,878.28 | 1,674.93 | 1,052.79 | 760.21 | 658.86 | 509.92 | 389.60 |
Average Common Equity |
735.73 | 824.24 | 822.57 | 752.71 | 675.05 | 487.32 | 338.09 | 300.35 | 249.23 | 218.68 |
Columns are period end dates